These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28373750)

  • 1. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
    Zhang Y; Wang Z; Hao X; Hu X; Wang H; Wang Y; Ying J
    Chin J Cancer Res; 2017 Feb; 29(1):18-24. PubMed ID: 28373750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon
    Jung HA; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
    Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33036377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
    Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
    Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups.
    Zhang Q; Cui Y; Zhang J; Kenjiabieke J; Aerxiding P
    Exp Ther Med; 2020 Jun; 19(6):3513-3520. PubMed ID: 32346412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
    Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
    J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
    Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
    Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.
    Chen D; Song Z; Cheng G
    Onco Targets Ther; 2016; 9():4181-6. PubMed ID: 27468240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature.
    Li L
    Heliyon; 2022 Sep; 8(9):e10407. PubMed ID: 36119883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
    Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
    Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
    Leal JL; Alexander M; Itchins M; Wright GM; Kao S; Hughes BGM; Pavlakis N; Clarke S; Gill AJ; Ainsworth H; Solomon B; John T
    Clin Lung Cancer; 2021 Nov; 22(6):e859-e869. PubMed ID: 34127383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon
    Shi J; Yang H; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Jia Y; Wang Y; Xi L; Zhang S; Su C; Ren S; Zhou C
    Chin J Cancer Res; 2017 Dec; 29(6):543-552. PubMed ID: 29353977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
    Kuiper JL; Hashemi SM; Thunnissen E; Snijders PJ; Grünberg K; Bloemena E; Sie D; Postmus PE; Heideman DA; Smit EF
    Br J Cancer; 2016 Dec; 115(12):1504-1512. PubMed ID: 27875527
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Xu H; Yang G; Liu R; Yang Y; Li W; Li J; Hao X; Xing P; Wang Y
    Front Pharmacol; 2022; 13():976731. PubMed ID: 36188595
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of uncommon
    Zhang T; Wan B; Zhao Y; Li C; Liu H; Lv T; Zhan P; Song Y
    Transl Lung Cancer Res; 2019 Jun; 8(3):302-316. PubMed ID: 31367543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.